GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 37,508 shares, a drop of 84.0% from the January 29th total of 234,255 shares. Based on an average trading volume of 98,162 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.8% of the company’s shares are sold short. Approximately 3.8% of the company’s shares are sold short. Based on an average trading volume of 98,162 shares, the days-to-cover ratio is presently 0.4 days.

GlucoTrack Stock Down 5.5%

NASDAQ GCTK traded down $0.09 during trading hours on Friday, reaching $1.55. 8,699 shares of the company’s stock were exchanged, compared to its average volume of 93,280. The company’s 50-day moving average is $2.92 and its two-hundred day moving average is $4.93. GlucoTrack has a one year low of $1.44 and a one year high of $30.51. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.53 and a current ratio of 1.53. The company has a market capitalization of $1.57 million, a price-to-earnings ratio of -0.04 and a beta of 0.32.

Institutional Investors Weigh In On GlucoTrack

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in GlucoTrack by 102,125.0% in the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after purchasing an additional 4,085 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack in the 4th quarter valued at about $52,000. Finally, Ikarian Capital LLC acquired a new position in shares of GlucoTrack during the fourth quarter worth about $177,000. 10.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.